These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

549 related items for PubMed ID: 10698045

  • 1. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly.
    Waśko R, Ruchała M, Sawicka J, Kotwicka M, Liebert W, Sowiński J.
    J Endocrinol Invest; 2000 Jan; 23(1):12-8. PubMed ID: 10698045
    [Abstract] [Full Text] [Related]

  • 2. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
    Waśko R, Bolko P, Kostrzewski J, Horst-Sikorska W, Liebert W, Sowiński J.
    Pol Arch Med Wewn; 2001 Aug; 106(2):693-8. PubMed ID: 11926144
    [Abstract] [Full Text] [Related]

  • 3. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R.
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M, Gussoni G, Cuttica CM, Giordano G.
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [Abstract] [Full Text] [Related]

  • 5. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G.
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [Abstract] [Full Text] [Related]

  • 6. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G.
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [Abstract] [Full Text] [Related]

  • 7. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA.
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [Abstract] [Full Text] [Related]

  • 8. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A.
    Neuroendocrinology; 2006 Mar; 83(3-4):249-57. PubMed ID: 17047390
    [Abstract] [Full Text] [Related]

  • 9. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.
    Suliman M, Jenkins R, Ross R, Powell T, Battersby R, Cullen DR.
    J Endocrinol Invest; 1999 Jun; 22(6):409-18. PubMed ID: 10435849
    [Abstract] [Full Text] [Related]

  • 10. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P.
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [Abstract] [Full Text] [Related]

  • 11. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
    al-Maskari M, Gebbie J, Kendall-Taylor P.
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
    [Abstract] [Full Text] [Related]

  • 12. Results of a two-year treatment with slow release lanreotide in acromegaly.
    Cannavò S, Squadrito S, Curtò L, Almoto B, Vieni A, Trimarchi F.
    Horm Metab Res; 2000 Jun; 32(6):224-9. PubMed ID: 10898551
    [Abstract] [Full Text] [Related]

  • 13. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.
    Tutuncu Y, Berker D, Isik S, Ozuguz U, Akbaba G, Kucukler FK, Aydin Y, Guler S.
    Pituitary; 2012 Sep; 15(3):398-404. PubMed ID: 21863263
    [Abstract] [Full Text] [Related]

  • 14. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
    Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G.
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2112-8. PubMed ID: 16537687
    [Abstract] [Full Text] [Related]

  • 15. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
    Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, Rowlers S, Trainer PJ, Wass JA.
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
    [Abstract] [Full Text] [Related]

  • 16. Pregnancy in women after successful acromegaly treatment, including surgical removal of pituitary adenoma and postoperative therapy using lanreotide acetate.
    Teltayev D, Akshulakov S, Ryskeldiev N, Mustafin K, Vyacheslav L.
    Gynecol Endocrinol; 2017 Jun; 33(sup1):50-51. PubMed ID: 29264984
    [Abstract] [Full Text] [Related]

  • 17. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.
    Kendall-Taylor P, Miller M, Gebbie J, Turner S, al-Maskari M.
    Pituitary; 2000 Oct; 3(2):61-5. PubMed ID: 11141697
    [Abstract] [Full Text] [Related]

  • 18. [Novel pharmacologic therapies in acromegaly].
    Góth M, Hubina E, Kovács L, Szabolcs I.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
    Cannavò S, Squadrito S, Curtò L, Almoto B, Trimarchi F.
    Horm Metab Res; 2001 Oct 12; 33(10):618-24. PubMed ID: 11607883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.